About Kritika Sarmah

Her interest in risky instruments and passion for writing made Kritika an analyst and financial journalist. She earned her bachelor's degree in commerce and is currently pursuing the CFA program. With her fundamental approach, she aims to help investors identify untapped investment opportunities.


Recent Articles By Kritika Sarmah

: GE |  News, Ratings, and Charts

3 Industrial Stocks Targeting Major Gains in 2024

The global industrial market is driven by the consistent growth of the industrial manufacturing and services sector. Hence, fundamentally sound industrial stocks General Electric (GE), AptarGroup (ATR), and Limbach Holdings (LMB) might be solid buys for gains next year. Read more...
: STN |  News, Ratings, and Charts

4 Outsourcing Stocks With Potential for End-of-Year Triumph and Beyond

The outsourcing industry is evolving significantly, driven by trends like nearshore outsourcing, IT solutions, and workforce outsourcing. Hence, fundamentally strong outsourcing stocks Stantec (STN), ManpowerGroup (MAN), Adtalem Global Education (ATGE), and Mitie Group (MITFY) might be solid buys for year-end gains. Read on...
: MSFT |  News, Ratings, and Charts

Evaluating 2024 Buying Potential of 3 Software Stocks

The software industry flourishes with intensified digitization, a prominent shift toward cloud-based solutions, and growing demand across various verticals. Hence, let us analyze leading software stocks Microsoft (MSFT), Brightcove (BCOV), and Cloudflare (NET) to evaluate their buying potential for 2024. Read more…
: VRTX |  News, Ratings, and Charts

Top 3 Biotech Stocks for Weekly End-of-Year Profits

In the ever-evolving realm of biotechnology, technological advancements and breakthroughs are propelling significant growth. Hence, fundamentally strong biotech stocks Equillium (EQ), United Therapeutics (UTHR), and Vertex Pharmaceuticals (VRTX) might be solid investments for weekly year-end gains. Read more…
: GMAB |  News, Ratings, and Charts

3 Biotech Stocks to Boost Portfolios

The biotech sector, fueled by genetic breakthroughs and digital innovations, is witnessing unprecedented growth. Hence, fundamentally sound biotech stocks Genmab (GMAB), Jazz Pharmaceuticals (JAZZ), and Exelixis (EXEL) might give a solid boost to one’s portfolio. Keep reading...
: TNL |  News, Ratings, and Charts

Top 3 Travel Stocks for Smart Investors

The evolving travel industry is marked by heightened demand and digitalization. Hence, fundamentally solid travel stocks Bluegreen Vacations (BVH), Travel + Leisure (TNL), and Atour Lifestyle (ATAT) might be solid buys for smart investors. Read more…
: ADM |  News, Ratings, and Charts

3 Agriculture Stocks With December Profit Potential

The demand for agricultural produce is increasing steadily, driven by the expanding global population. Therefore, fundamentally strong agriculture stocks Archer-Daniels-Midland (ADM), Bunge (BG), and Dole (DOLE) with profit potential might be ideal buys this month. Read on...
: MSFT |  News, Ratings, and Charts

3 Software Stocks With Potential for End-of-Year Success

The software industry thrives with heightened demand driven by increased digitization and a notable shift toward cloud-based solutions. Hence, fundamentally strong software stocks Microsoft (MSFT), Docebo (DCBO), and Kaltura (KLTR) might be solid buys now for year-end gains. Read more…
: STLA |  News, Ratings, and Charts

STLA, F, and TSLA: Auto Stock Buy, Hold, or Sell?

Despite challenges, increasing customer interest in electric vehicles (EVs) and advancements in autonomous driving technology are fueling the auto manufacturing industry. So, let us analyze whether to Buy, Hold, or Sell leading auto stocks Stellantis (STLA), Ford Motor (F), and Tesla (TSLA). Continue reading...
: LLY |  News, Ratings, and Charts

3 Rising Pharma Stocks to Consider Buying Now

The pharmaceutical sector is transforming due to the swift uptake of digital solutions and worldwide spending growth. Hence, fundamentally strong pharma stocks Supernus Pharmaceuticals (SUPN), Astellas Pharma (ALPMY), and Eli Lilly (LLY) might be solid buys now. Read more…
Page generated in 1.2799 seconds.